



Biotech Daily

Thursday January 23, 2020

Daily news on ASX-listed biotechnology companies

- * **ASX, BIOTECH DOWN: PRESCIENT UP 11%; USCOM DOWN 14%**
- * **EMERALD RAISES \$6m OF \$8m FOR MARIJUANA, DATA IPO**
- * **US FDA OKAYS TELIX ZIRCON RENAL CANCER TRIAL**
- * **MACH7 H1 RECEIPTS UP 89% TO \$8.3m**
- * **USCOM H1 RECEIPTS UP 21.6% TO \$1.1m**
- * **BIOTRON PLEADS SCHULTZ, DIRECTORS, MEETING TO ASX 40% QUERY**
- * **AUSTRALIAN ETHICAL TAKES 5% OF IMPEDIMED**
- * **MERCHANT TAKES 16% OF SIENNA**
- * **DAVID DAGLIO INCREASES, DILUTED TO 6% OF TOTAL BRAIN**
- * **G MEDICAL LISTS ON OTCQB**
- * **LIFESPOT REQUESTS CAPITAL RAISING TRADING HALT**
- * **CANN GLOBAL SUPPLIES T12 HEMP TO COSTCO**
- * **BARD1 APPOINTS PROF ALLAN CRIPPS DIRECTOR**

MARKET REPORT

The Australian stock market fell 0.63 percent on Thursday January 23, 2020, with the ASX200 down 44.7 points to 7,088.0 points. Fourteen of the Biotech Daily Top 40 stocks were up, 17 fell, eight traded unchanged and one was untraded.

Prescient was the best, up 0.6 cents or 11.1 percent to six cents, with 9.5 million shares traded. Mesoblast climbed 5.5 percent passing through \$3 a share; Paradigm and Neuren improved more than four percent; Dimerix and Telix were up more than three percent; Antisense and Genetic Signatures rose more than two percent; Medical Developments, Nanosonics and Opthea were up one percent or more; with Clinuvel, Resmed, Starpharma and Volpara up by less than one percent.

Uscom led the falls, down two cents or 14.3 percent to 12 cents with 100,000 shares traded. Actinogen lost 7.1 percent; both Imugene and Optiscan fell 5.7 percent; Cynata, Impedimed, Kazia, LBT, Oncosil and Pharmaxis were down more than three percent; Avita shed 2.1 percent; Cochlear, Immutep, Orthocell, Pro Medicus and Proteomics were down more than one percent; with Compumedics, CSL and Next Science down by less than one percent.

EMERALD CLINICS

Emerald Clinics says it raised \$6 million of up to \$8 million at 20 cents a share to list on the ASX to operate marijuana clinics and capture related “real world evidence”.

Emerald executive chairman Dr Stewart Washer told Biotech Daily the company had applications for more than \$8 million but chose to raise \$6 million to minimize dilution of early investors.

Emerald said it would have a market capitalization of \$36.8 million following the initial public offer and expected to list on the ASX under the code EMD in February 2020.

Last year, the Perth-based Emerald said it raised \$2.5 million in convertible notes ahead of a planned initial public offer, scheduled for April 2019 (BD: Feb 18, 2019).

Emerald said at that time that it operated medical marijuana clinics in Sydney and Perth and the 2019 capital raising was supported by Canada’s Canopy Growth Corp, Melbourne marijuana grower Cann Group and US cannabis investor CB1 Capital.

Dr Washer told Biotech Daily the convertible notes were at a 20 percent discount to the then proposed initial public offer price.

Today, Emerald said it had four “patient-focused medical clinics in Sydney, Melbourne, Perth and the Northern Rivers region of [New South Wales], providing safe access to unregistered medicines such as cannabinoid medicines for suitably qualified patients in collaboration with referring doctors”.

The company said it had about 1,000 patients and along with access, it would capture “anonymous, trial-grade and regulator-ready real-world data from the patients”.

Emerald said the lack of high-quality clinical evidence contributed to a restriction on patient access and it had “multiple anonymous patient data deals with customers including Spectrum Therapeutics, the medical division of ... Canopy Growth”.

Emerald said the funds raised in the initial public offer would be used to further develop its data platform, establishing clinics in Australia and the UK, conduct clinical trials and progress business objectives including liaison with potential data customers.

Emerald chief executive officer Dr Michael Winlo said that “a perfect storm in the medicinal cannabis sector makes it the right time for the company’s offering”.

The company said the board included Dr Washer, Dr Winlo, executive director Dr Alistair Vickery, non-executive director Matthew Callahan and proposed non-executive director John Tooke, with co-founder Adam James appointed as its chief operating officer.

The company said that PAC Partners was the lead manager to the offer.

Emerald is a public unlisted company.

TELIX PHARMACEUTICALS

Telix says the US Food and Drug Administration has approved its 250-patient, phase III zirconium imaging in renal cancer oncology (Zircon) trial.

Telix said recruitment of US patients would begin in 30 days and the study would assess TLX250-CDx for the imaging of clear cell renal cell cancer using positron emission tomography.

The company said it was currently recruiting at 19 sites in Australia and Europe and with the receipt of an investigational new drug notice of allowance, would add six cancer centres in the US.

Telix chief executive officer Dr Christian Behrenbruch said the approval was “a major milestone for the company in terms of moving ahead the Zircon study as well as engagement with US regulators for a late-stage trial”.

Telix said it expected to complete enrolment “around mid-year”.

Telix was up five cents or 3.45 percent to \$1.50 with 825,307 shares traded.

MACH7 TECHNOLOGIES

Mach7 says receipts from customers for the six months to December 31, 2019 were up 88.7 percent to \$8,296,000.

In its Appendix 4C quarterly report, Mach7 said it had cash and cash equivalents of \$23,279,000 at December 31, 2019 and expected a cash burn for the three months to March 31, 2020 of \$3,805,000.

Mach7 was up 2.5 cents or 3.4 percent to 76 cents with 2.05 million shares traded.

USCOM

Uscom says receipts from customers for the six months to December 31, 2019 were up 21.6 percent to \$1,113,505.

In its Appendix 4C quarterly report, Uscom said it had cash and cash equivalents of \$1,483,006 at December 31, 2019 and expected a cash burn for the three months to March 31, 2020 of \$985,000.

Uscom fell two cents or 14.3 percent to 12 cents.

BIOTRON

Biotron has told the ASX that it is not aware of any information it has not announced which, if known, could explain recent trading in its securities.

The ASX said the company's share price rose 40 percent from 6.0 cents to 8.4 cents on January 22, 2020 and noted a significant increase in the trading volume.

Biotron said directors Prof Stephen Locarnini and Robert Thomas increased their holdings off-market, filing change of director's interest notices on January 13 and 22, respectively.

The company said that in December 2019 it announced it would present clinical trial data on BIT225 for HIV-1 at the Conference on Retroviral and Opportunistic Infections and had filed two patent applications to expand the use of BIT225 and its other anti-HIV-1 compounds.

Biotron fell 1.5 cents or 17.9 percent to 6.9 cents with 66.8 million shares traded.

IMPEDIMED

Australian Ethical Investment says it has become a substantial shareholder in Impedimed with 27,759,024 shares (5.43%).

The Sydney-based Australian Ethical said that between December 3, 2019 and January 21, 2020 it acquired 6,905,015 shares for \$1,125,683 or an average of 16.3 cents a share. Impedimed fell half a cent or 3.7 percent to 13 cents with 2.5 million shares traded.

SIENNA CANCER DIAGNOSTICS

Perth's Merchant Funds Management says it has increased its holding in Sienna Cancer Diagnostics from 29,764,649 shares (10.99%) to 63,476,191 shares (16.06%).

Merchant said that between December 16, 2019 and January 20, 2020 it bought the shares in the recent \$3.7 million capital raising at 3.5 cents a share (BD: Jan 21, 2020).

Sienna fell 0.2 cents or 4.9 percent to 3.9 cents.

TOTAL BRAIN

Boston's David Daglio Jr says he has increased and been diluted in Total Brain from 50,301,809 shares (6.47%) to 69,501,809 shares (6.42%).

Mr Daglio said that on November 14, 2019 he acquired 19,200,000 shares for \$883,200 or 4.6 cents a share and was diluted in the \$14 million private placement (BD: Nov 8, 2019). Total Brain was untraded at 72 cents.

G MEDICAL INNOVATIONS HOLDINGS

G Medical says it has listed on the Over-The-Counter Quality Exchange second board (OTCQB) under the ticket code GMMVF.

Last August, G Medical said it had withdrawn its \$25 million Nasdaq registration statement and would pursue an OTCQB listing (BD: Aug 26, 2019).

G Medical was up half a cent or three percent to 17 cents with 4.1 million shares traded.

LIFESPOT HEALTH

Lifespot has requested a trading halt "pending an announcement in relation to a proposed capital raising".

Trading will resume on January 28, 2020 or on an earlier announcement.

Lifespot last traded at 3.4 cents.

CANN GLOBAL

Cann Global says it will supply T12 hemp powder to wholesale food retailer Costco Australia and Vietnam's Epco Foods has increased its supply request by 50 percent.

Cann Global said it had continuing orders with Costco for T12 hemp seed oil capsules and new orders for its Blanck & Co hemp protein natural and vanilla flavors.

The company said the Ho Chi Minh City-based Epco Foods would provide further product orders for T12 food additive capsules, including for chia, fish oil and flax products.

Cann Global was up 0.1 cents or 6.25 percent to 1.7 cents with 24.2 million shares traded.

BARD1 LIFE SCIENCES

Bard1 says it has appointed Prof Allan Cripps as a non-executive director, effective today.

Bard1 said Prof Cripps was the health pro-vice-chancellor at Brisbane's Griffith University for 11 years, was currently a research professor at Griffith University and was awarded the Order of Australia in 2015.

The company said Prof Cripps was currently the chair of the Children's Research Alliance Board and was previously a director of Research Australia and the Gold Coast Hospital and Health Services Board.

Bard1 said Prof Cripps held a Bachelor of Science from the Armidale-based University of New England and a Doctor of Philosophy from the University of Sydney.

Bard1 was unchanged at 3.4 cents with 6.4 million shares traded.